All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-08-10T12:09:50.000Z

What is on the horizon for treating peripheral T-cell lymphoma?

By Camilla Rossi, Erika Roa, Mark Maitland, Quintina Dawson
Featured
Neha Mehta-Shah
Aug 10, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in T-cell lymphoma.

Bookmark this article

During the Pan Pacific Lymphoma Congress, the Lymphoma Hub spoke with Neha Mehta-Shah, Washington University School of Medicine, St. Louis, US. We asked, What is on the horizon for treating peripheral T-cell lymphoma?

What is on the horizon for treating peripheral T-cell lymphoma?

Mehta-Shah begins by outlining the drug classes of some emerging treatments for peripheral T-cell lymphoma, including JAK and STAT inhibitors. Mehta-Shah also touches on the PRIMO study, investigating duvelisib and other PI3 kinase inhibitors. Finally, Mehta-Shah highlights new studies investigating allogeneic CAR T-cells and discusses the VALENTINE study.

 

More about...
DuvelisibKinase inhibitorsMature T and NK cell neoplasmsPeripheral T-cell lymphomaPPLC22PRIMO

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Duvelisib receives Orphan Drug designation from the FDA for the treatment of T-cell lymphoma

On the 3rd of October 2019 the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for duvelisib as a treatment for patients with T-cell...

Oct 4, 2019
Add bookmark

Duvelisib receives Orphan Drug designation from the FDA for the treatment of T-cell lymphoma

On the 3rd of October 2019 the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for...

Oct 4, 2019
Add bookmark

Educational theme: Advances in T-cell lymphomas

Throughout May, the Lymphoma Hub will be focusing on a new educational theme of “Advances in T-cell lymphomas”. This article introduces the topic of T-cell lymphomas and summarizes some of the latest...

May 13, 2020
Add bookmark

Educational theme: Advances in T-cell lymphomas

Throughout May, the Lymphoma Hub will be focusing on a new educational theme of “Advances in T-cell lymphomas”. This article introduces the topic of...

May 13, 2020

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox